These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6134517)

  • 81. The relationship of the brief psychiatric rating scale to neuropsychological deficits in phenothiazine-treated schizophrenics.
    Golden CJ; Carpenter B; Wilkening G; Ruedrich S; Chu CC; Graber B
    Psychopharmacol Bull; 1983; 19(3):513-7. PubMed ID: 6138799
    [No Abstract]   [Full Text] [Related]  

  • 82. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Clinical characteristics of chronic schizophrenic patients presenting with severe anhedonia].
    Loas G; Noisette C; Legrand A; Boyer P; Delahousse J
    Encephale; 1996; 22(5):351-8. PubMed ID: 9035991
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
    Gattaz WF; Rost W; Hübner CK; Bauer K
    Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Plasma levels of phenylacetic acid, m- and p-hydroxyphenylacetic acid, and platelet monoamine oxidase activity in schizophrenic and other patients.
    Davis BA; Yu PH; Carlson K; O'Sullivan K; Boulton AA
    Psychiatry Res; 1982 Feb; 6(1):97-105. PubMed ID: 6120530
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Involuntary disorders of movement in chronic schizophrenia--the role of the illness and its treatment.
    Owens DG
    Psychopharmacology Suppl; 1985; 2():79-87. PubMed ID: 2860663
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cerebrospinal fluid zinc concentrations in ex-heroin addicts and patients with schizophrenia: some preliminary observations.
    Potkin SG; Shore D; Torrey EF; Weinberger DR; Gillin JC; Henkin RI; Agarwal RP; Wyatt RJ
    Biol Psychiatry; 1982 Nov; 17(11):1315-22. PubMed ID: 6129905
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients.
    Katila H; Hurme M; Wahlbeck K; Appelberg B; Rimón R
    Neuropsychobiology; 1994; 30(1):20-3. PubMed ID: 7969854
    [TBL] [Abstract][Full Text] [Related]  

  • 91. ERPs in schizophrenia: effects of antipsychotic medication.
    Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
    Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [14C]-beta-phenethylamine, its distribution after administration by various routes to cats, and the effects of monoamine oxidase inhibitors.
    Garcha G; Imrie PR; Marley E; Thomas DV
    Br J Pharmacol; 1985 Dec; 86(4):877-88. PubMed ID: 4075021
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Neuroleptic effects on serine and glycine metabolism.
    Baruah S; Waziri R; Sherman A
    Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study.
    Weber-Fahr W; Englisch S; Esser A; Tunc-Skarka N; Meyer-Lindenberg A; Ende G; Zink M
    Psychiatry Res; 2013 Dec; 214(3):365-73. PubMed ID: 24045051
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Discrimination between and among schizophrenics and other pathologies using a Spanish version of the Whitaker Index of Schizophrenic Thinking.
    Godoy JF; Fernandez M; Muela JA; Roldan G; Catena A; Puente AE
    J Clin Psychol; 1994 Mar; 50(2):158-61. PubMed ID: 8014238
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
    Bowers MB; Heninger GR
    Psychiatry Res; 1981 Jun; 4(3):285-90. PubMed ID: 6115436
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Association between regional brain volumes and clozapine response in schizophrenia.
    Lauriello J; Mathalon DH; Rosenbloom M; Sullivan EV; Faustman WO; Ringo DL; Lim KO; Pfefferbaum A
    Biol Psychiatry; 1998 Jun; 43(12):879-86. PubMed ID: 9627742
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Longitudinal effect of amitriptyline and fluoxetine treatment on plasma phenylacetic acid concentrations in depression.
    Davis BA; Boulton AA; Yu PH; Durden DA; Keegan DL; Bowen RC; Blackshaw S; D'Arcy C; Remillard AJ; Dayal N
    Biol Psychiatry; 1991 Sep; 30(6):600-8. PubMed ID: 1932407
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Delta-sleep inducing peptide in cerebrospinal fluid from schizophrenics, depressives and healthy volunteers.
    Lindström LH; Ekman R; Walleus H; Widerlöv E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(1):83-90. PubMed ID: 2859636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.